Skip to main content
GH logo

Guardant Health, Inc. (GH) Stock: Price, Forecast & Analyst Target

Guardant Health, Inc. (GH) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $145.14 (+1.30%), as of the Nov 18, 2026 trading session; market cap $19.6B.

Educational signal · not a buy or sell recommendation · How to read this

$145.14 +$1.86 (+1.30%) Market Cap $19.6B

Guardant Health, Inc. · GH · NASDAQ · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-12: Guardant Health sells liquid-biopsy and tissue-based oncology tests, cancer screening, clinical-genomic analytics and development services for biopharma customers. Revenue is expanding quickly, but screening investment and rising operating expense still keep cash flow negative; durability depends on closing that gap without exhausting the balance-sheet cushion.

Price as of Nov 18, 2026

Key Statistics

34 of 100

MoonshotScore v2 · Guardant Health (GH)

Weak
Business Quality Solid (61)
Financial Safety Strained (31)
Valuation Full (55)
Growth Durability Flat (56)
Momentum Surging (86)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strained balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $265M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 3.38 · Piotroski F 3

Holding back: balance-sheet strain

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GH (57 recorded, newest six shown)
RecordedScoreBand
33Weak
34Weak
34Weak
34Weak
34Weak
34Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$145.14
Change on the day+1.30%
52-week range$74.55–$191.05
Market capitalisation$19.6B—
Price / earnings (trailing)-243.47
Shares traded on the day1.50M
Beta (volatility vs the S&P 500)1.66

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $65, high $179, latest $145. $179 $65 high $179 Oct 17, 2025 Nov 18, 2026 · $145 $65Oct 17, 2025$93Oct 31, 2025$94Nov 14, 2025$108Nov 28, 2025$102Dec 12, 2025$103Dec 26, 2025$110Jan 9, 2026$115Jan 23, 2026$102Feb 6, 2026$103Feb 20, 2026$91Mar 6, 2026$85Mar 20, 2026$94Apr 2, 2026$90Apr 17, 2026$88May 1, 2026$95May 15, 2026$130May 29, 2026$132Jun 12, 2026$149Jun 26, 2026$160Jul 10, 2026$147Jul 24, 2026$168Aug 7, 2026$171Aug 21, 2026$161Sep 4, 2026$179Sep 18, 2026$178Oct 2, 2026$159Oct 16, 2026$179Oct 30, 2026$152Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Guardant Health (GH): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Guardant Health (GH), and what does it report?

Short answer · as of

Guardant is a precision-oncology platform rather than a developer of cancer medicines.

It earns revenue from testing patients with advanced or early-stage cancer, screening asymptomatic people, supplying clinical-genomic analytics, and supporting biopharma customers with companion diagnostics and clinical development services.

Reported revenue primarily reflects Oncology, Biopharma & Data, and the emerging Screening business, with licensing and other activity contributing little. Oncology remains the commercial base, while Screening and data services expose the company to distinct adoption cycles and spending requirements.

2 · Latest results

What do the latest results show for Guardant Health (GH)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $265M.

The latest quarter extended the revenue climb across the displayed history, and gross profit rose with it. Operating and net losses nevertheless widened from the preceding period as selling and administrative expense climbed and research spending remained heavy. Revenue has also cleared consensus throughout the earnings history shown, while per-share results have been uneven.

Management’s outlook calls for further expense growth, says the business outside Screening should generate positive free cash flow, and retains a companywide cash-flow breakeven goal. That framing identifies Screening as the principal bridge between strong commercial momentum and the intended cash profile.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$265M-$93M-$0.74 (diluted)
Q4 FY2025$281M-$128M-$1.00 (diluted)
Q1 FY2026$302M-$112M-$0.85 (diluted)
Q2 FY2026$335M-$120M-$0.90 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Guardant Health (GH)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and investments provide substantial operating runway at the recent pace of cash use, and near-term liquidity ratios remain strong. The company is not in a net-cash position, however: debt exceeds cash and short-term investments, while operations and capital spending continue to consume cash.

Management’s carve-out of Screening from expected positive free cash flow makes that business the visible funding burden. If commercial growth slows while selling expense remains elevated, persistent losses could continue despite healthy gross margins and ample liquidity.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Guardant Health (GH)?

Short answer · as of

Current published price targets run low $180.00 · high $225.00 · consensus $203.40 · median $200.00 against a quoted price of $145.14 (as of Nov 18, 2026).

Consensus expects another revenue step-up and a much smaller per-share loss at the scheduled earnings release. Delivery on revenue without a corresponding improvement in operating loss or cash use would repeat the pattern already visible in recent results.

Reveal Ultra provides the near-term product marker. Launch progress and continued Reveal momentum should be read alongside segment mix and cash generation: Screening must become less burdensome while Oncology and Biopharma & Data sustain the commercial base.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Guardant Health compare with its peers?

Short answer

Guardant Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Guardant combines advanced-cancer liquid biopsy, residual-disease testing, cancer screening and biopharma analytics built around a clinical-genomic dataset. Unlike a drug developer, it sells tests, datasets and development support rather than depending on sales of a therapy.

Compared with a testing-only laboratory, GuardantINFORM and companion-diagnostic services make biopharma research clients part of the model. That breadth creates distinct routes to adoption, but it also requires concurrent spending across established oncology products and the newer Screening business.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Ascendis Pharma A/S (ASND) Named competitor$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1737.26 Nov 18, 2026$34.6B93 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Same industry, near in market value$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Same industry, near in market value$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Qiagen N.V. (QGEN) Same industry, near in market value$49.56 Nov 18, 2026$10.2B83 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Same industry, near in market value$259.52 Nov 18, 2026$28.6B74 5-pillar Nov 18, 2026
ICON Public Limited Company (ICLR) Same industry, near in market value$195.16 Nov 18, 2026$14.6B73 5-pillar Nov 18, 2026
Revvity, Inc. (RVTY) Same industry, near in market value$152.43 Nov 18, 2026$17.0B71 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Same industry, near in market value$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Charles River Laboratories International, Inc. (CRL) Same industry, near in market value$333.25 Nov 18, 2026$16.0B70 5-pillar Nov 18, 2026
Solventum Corporation (SOLV) Named competitor$86.48 Nov 18, 2026$14.7B66 5-pillar Nov 18, 2026
Natera, Inc. (NTRA) Same industry, near in market value$289.50 Nov 18, 2026$42.0B36 5-pillar Nov 18, 2026
Guardant Health (GH) — this page$145.14$19.6B34

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$180.00 – $225.00
Consensus target
$203.40
Median target
$200.00

Consensus record · Captured .

Measured against a quoted price of $145.14 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
58
Identified insiders
12
Purchases
0
Sales
2
Other transactions
56

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GH in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.62%$108.30MAdded +19.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Guardant Health (GH)?

Read these with our analysis →

What Investors Ask About Guardant Health (GH) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does Reveal Ultra add to Guardant Health’s residual-disease strategy?

Management presents Reveal Ultra as a more sensitive tumor-informed residual-disease test and pairs its planned launch with continued commercial momentum for Reveal. Its importance lies in adoption within early-stage cancer care, rather than merely expanding the advanced-cancer assay menu.

Why does Screening matter so much to Guardant Health’s cash burn?

Management expects the business outside Screening to generate positive free cash flow while consolidated operations remain cash-consuming. That carve-out makes Screening the key funding burden to track as revenue scales.

What does GuardantINFORM sell to biopharma customers?

GuardantINFORM turns the company’s clinical-genomic liquid-biopsy dataset into an in-silico research platform. It extends the business from processing patient tests into supplying analytical utility to research and clinical clients.

Why have Guardant Health’s revenue beats not produced profits?

Revenue has repeatedly exceeded estimates, but selling, administrative and research spending remain above gross profit, leaving operating and net results negative. The widening latest loss shows that top-line momentum has not yet delivered operating leverage.

What is the GH stock price today?

The last price recorded for Guardant Health, Inc. (GH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GH price target?

The analyst consensus price target for Guardant Health, Inc. (GH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Guardant Health (GH), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Guardant Health (GH)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Guardant Health (GH)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 4. What should you watch next at Guardant Health (GH)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Revenue by segment; Management outlook — dated call excerpts
  • 5. How does Guardant Health compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Management outlook — dated call excerpts
  • FAQ: What does Reveal Ultra add to Guardant Health’s residual-disease strategy?: Business description; Management outlook — dated call excerpts
  • FAQ: Why does Screening matter so much to Guardant Health’s cash burn?: Revenue by segment; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • FAQ: What does GuardantINFORM sell to biopharma customers?: Business description; Revenue by segment
  • FAQ: Why have Guardant Health’s revenue beats not produced profits?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold GH

Funds in our ETF coverage that list GH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Global X - Genomics & Biotechnology ETF (GNOM)4.71%